---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-043166"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2025-03-21T23:59:59+00:00"
generated_at: "2026-05-24T08:57:53.214422+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tivic Health FY2024 net loss narrows to $5.7M; secures $25M equity line, in-licenses Entolimod

## Summary
- FY2024 revenue $0.8M (down from $1.2M); net loss -$5.7M vs -$8.2M in 2023 (30% decrease).
- Entered $25M equity purchase agreement with Mast Hill Fund; issued 29,800 commitment shares.
- In-licensed late-stage TLR5 agonist Entolimod from Statera Biopharma for acute radiation syndrome (Phase III).
- Appointed Michael Handley as COO and President of Tivic Biopharma; Lisa Wolf as interim CFO.
- ncVNS optimization study completed enrollment; disease-specific trials planned in 2025.

## SEC filing metadata
- accession: 0000950170-25-043166
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2025-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017025043166/0000950170-25-043166-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017025043166/tivc-20250318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-043166
- JSON: https://secwatch.observer/filing/0000950170-25-043166.json
- Plain text: https://secwatch.observer/filing/0000950170-25-043166.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.